Who is the manufacturer of EOGas 4 Endo-SteriTest?

Andersen Sterilizers, Inc. filed the 510(k) submission for EOGas 4 Endo-SteriTest (K192980).

What is the FDA product code for EOGas 4 Endo-SteriTest?

FRC. It is classified under 21 CFR 880.2800 as a Class 2 device in the General Hospital panel.

What is the regulatory pathway for EOGas 4 Endo-SteriTest?

510(k) clearance (submission type: Traditional).

Who can help prepare an FDA 510(k) submission like EOGas 4 Endo-SteriTest?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

EOGas 4 Endo-SteriTest

K192980 · Andersen Sterilizers, Inc. · FRC · Nov 12, 2020 · General Hospital

Device Facts

Record ID	K192980
Device Name	EOGas 4 Endo-SteriTest
Applicant	Andersen Sterilizers, Inc.
Product Code	FRC · General Hospital
Decision Date	Nov 12, 2020
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 880.2800
Device Class	Class 2

Indications for Use

The EOGas 4 Endo-SteriTest consists of a self-contained biological indicator inoculated with viable Bacillus atrophaeus bacterial spores that is placed in a dedicated biological indicator receptacle mounted on a gold-colored purge probe in the sterilizer. It monitors the efficacy of the 6-hour gas exposure at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer.

Device Story

The EOGas 4 Endo-SteriTest is a self-contained biological indicator (SCBI) used to monitor ethylene oxide (EO) sterilization efficacy. It consists of a plastic vial containing Bacillus atrophaeus spores on a paper carrier and a glass ampoule of growth medium with a pH indicator. The operator places the SCBI into a reusable receptacle on a gold-colored purge probe inside the EOGas 4 sterilizer. After a 6-hour cycle, the operator retrieves and activates the SCBI by crushing the ampoule. A chemical indicator on the label changes color to confirm EO exposure. The SCBI is incubated for 48 hours; a color change from red-orange to yellow or turbidity indicates sterilization failure, while no change indicates success. The device provides healthcare providers with a biological challenge to verify that sterilization parameters (EO concentration, temperature, humidity, time) were met, ensuring the safety of processed endoscopes.

Clinical Evidence

Bench testing only. Studies included viable spore population assays, resistance characteristics (D-value), growth inhibition, holding time assessment, and reduced incubation time validation per FDA 2007 BI guidance and ANSI/AAMI/ISO 11138-1. Performance testing confirmed the device provides a rigorous challenge to the sterilization process, with partial kill in half-dose cycles and complete kill in full-dose cycles. Endpoint color stability was verified for 28 days.

Technological Characteristics

SCBI consisting of paper carrier, glass ampoule, polypropylene vial, and stainless steel receptacle. Sensing principle: biological indicator (Bacillus atrophaeus spores) and chemical indicator (pH-based color change). Dimensions/form factor: self-contained vial. Sterilization method: ethylene oxide. Connectivity: none (standalone).

Indications for Use

Indicated for monitoring the efficacy of 6-hour ethylene oxide gas sterilization cycles at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer using Bacillus atrophaeus spores.

Regulatory Classification

Identification

Biological sterilization process indicator: A device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor adequacy of sterilization. The device consists of a known number of microorganisms, of known resistance to the mode of sterilization, in or on a carrier and enclosed in a protective package. Subsequent growth or failure of the microorganisms to grow under suitable conditions indicates the adequacy of sterilization. Physical/chemical sterilization process indicator: A device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor one or more parameters of the sterilization process. The adequacy of the sterilization conditions as measured by these parameters is indicated by a visible change in the device.

Predicate Devices

EOGas 4 SteriTest (K151585)

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. November 12, 2020 Andersen Sterilizers, Inc. William Andersen President 3154 Caroline Drive Haw River, North Carolina 27258 Re: K192980 Trade/Device Name: EOGas 4 Endo-SteriTest Regulation Number: 21 CFR 880.2800 Regulation Name: Sterilization Process Indicator Regulatory Class: Class II Product Code: FRC Dated: October 28, 2020 Received: October 29, 2020 #### Dear William Andersen: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part {1}------------------------------------------------ 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, CAPT Elizabeth Claverie, MS Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below. 510(k) Number (if known) K192980 Device Name EOGas 4 Endo-SteriTest Indications for Use (Describe) The EOGas 4 Endo-SteriTest consists of a seff-contained biological indicator inoculated with viable Bacillus atrophaeus bacterial spores that is placed in a dedicated biological indicator receptacle mounted on a gold-colored purge probe in the sterilizer. It monitors the efficacy of the 6-hour gas exposure at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer. Critical process parameters for the cycle are summarized in Table 1. Table 1. Critical parameters for the 6-hour gas exposure in the EOGas 4 Ethylene Oxide Gas Sterilizer | Ethylene Oxide | Temperature | Relative Humidity | EO Exposure Time | Total Cycle Time | |----------------|-------------|-------------------|------------------|------------------| | 17.6 g ± 5% | 50°C ± 3°C | 35-90% | 6 hours | 7 hours | Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) X Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. {3}------------------------------------------------ This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ # 510(k) Summary K192980 | Applicant's Name and Address | Andersen Sterilizers, Inc. 3154 Caroline Drive Haw River, NC 27258 | |---------------------------------|--------------------------------------------------------------------------| | Contact Person | William K. Andersen, BE, MD, FAAOS President | | | Phone: 336-376-8622, Fax: 336-376-5428 | #### Date of Preparation October 28, 2020 #### Device Proprietary Name Common Name Classification Product Code EOGas 4 Endo-SteriTest Biological Sterilization Process Indicator Class II (21 CFR 880.2800) FRC ## Predicate Device Device Name 510(k) number Manufacturer EOGas 4 SteriTest K151585 Andersen Sterilizers, Inc. This 510(k) submission modifies the predicate device to add a process challenge device for a 6hour gas exposure. No modifications were made to the technology or intended use. ## Device Description The EOGas 4 Endo-SteriTest consists of a single-use self-contained biological indicator (SCBI) placed in a reusable biological indicator (BI) receptacle. It is designed for monitoring the efficacy of the 6-hour gas exposure at 50°C in an EOGas 4 Ethylene Oxide Gas Sterilizer. The SCBI, the EZTest-Gas Biological Indicator, consists of a plastic vial that serves as the culture tube, and a cap including a filter material port to allow ethylene oxide to enter the vial. The plastic vial contains Bacillus atrophaeus spores inoculated onto a paper carrier, and a glass ampoule containing modified soybean casein digest broth and phenol red acting as a pH {5}------------------------------------------------ indicator. There is a chemical indicator printed on the unit label of the SCBI to indicate EO exposure. Following manufacturer's instructions, the operator inserts the EZTest-Gas Biological Indicator into the reusable BI receptacle on the dedicated purge probe of the EOGas 4 Ethylene Oxide Gas Sterilizer, and initiates a 6-hour gas exposure at 50℃. After cycle completion, the EZTest-Gas Biological Indicator is retrieved and activated by crushing the glass ampoule. The chemical indicator on the SCBI changes from blue to a green/brown color depending on the duration of ethylene oxide exposure. The activated SCBI and an unprocessed control are incubated at 30- 35°C for 48 hours and monitored for any color change and/or turbidity. Evidence of microbial growth by color change from red-orange to yellow and/or turbidity must be interpreted as a failure to meet the conditions necessary for sterilization (cycle failed); no color change or turbidity indicates conditions for sterilization were achieved (cycle passed). ## Indications for Use The EOGas 4 Endo-SteriTest consists of a self-contained biological indicator inoculated with viable Bacillus atrophaeus bacterial spores that is placed in a dedicated biological indicator receptacle mounted on a gold-colored purge probe in the sterilizer. It monitors the efficacy of the 6-hour gas exposure at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer. Critical process parameters for the cycle are summarized in Table 1. Table 1. Critical parameters for the 6-hour gas exposure in the EOGas 4 Ethylene Oxide Gas Sterilizer | Ethylene Oxide | Temperature | Relative Humidity | Ethylene Oxide Exposure Time | Total Cycle Time | |----------------|-------------|----------------------|---------------------------------|---------------------| | 17.6 g ± 5% | 50°C ± 3°C | 35-90% | 6 hours | 7 hours | # Technological Characteristics Comparison The technological characteristics of the EOGas 4 Endo-SteriTest are compared to the predicate device, EOGas 4 SteriTest (K151585), because both process challenge devices (PCDs) are intended for the same use, use the same technology, are designed in the same way, and perform similarly. The EOGas 4 Endo-SteriTest differs from the predicate device in the resistance to the sterilization process. A comparison between the devices is listed in Table 2. {6}------------------------------------------------ | Element | EOGas 4 SteriTest (K151585) | EOGas 4 Endo-SteriTest (K192980) | |------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Intended Use | Sterilization method: EO gas Process parameters: EO concentration, time, temperature, and relative humidity | Identical | | Organism | Bacillus atrophaeus (ATCC 9372) | Identical | | Viable Spore Population | ≥1.0 x $10^6$ | Identical | | Device Design | SCBI Paper strip containing indicator organism; Glass ampoule containing growth medium; Capped vial serving as a culture tube; A pH indicator in medium for color change; A process indicator indicating EO exposure. | SCBI Identical | | | BI receptacle Creates a greater challenge to the sterilization process than the worst-case location of the worst-case load in the IFU statement; For the 3-hour gas exposure | BI receptacle Same; Modified for a 6-hour gas exposure used for duodenoscope and colonoscope sterilization | | | Purge probe Blue color | Purge probe Gold color | | Materials of Construction | Paper, glass, polypropylene, and aluminum | Paper, glass, polypropylene, and stainless steel | | Configuration in Load | SCBI in a receptacle | Identical | | Indications for Use | The EOGas 4 SteriTest consists of a self- contained biological indicator inoculated with viable Bacillus atrophaeus bacterial spores that is placed in a dedicated BI receptacle in the sterilizer. It monitors the efficacy of the 3-hour gas exposure at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer. | The EOGas 4 Endo-SteriTest consists of a self-contained biological indicator inoculated with viable Bacillus atrophaeus bacterial spores that is placed in a dedicated BI receptacle in the sterilizer. It monitors the efficacy of the 6-hour gas exposure at 50°C in the EOGas 4 Ethylene Oxide Gas Sterilizer. | #### Table 2. Device Comparison # Summary of Non-Clinical Testing: The EOGas 4 Endo-SteriTest has been validated using applicable tests in FDA 2007 "Guidance for Industry and FDA Staff: Biological Indicator (BI) Premarket Notification [510(k)] Submissions", and ANSI AAMI ISO 11138-1 "Sterilization of health care products – Biological indicators - Part 1: General requirements" (FDA Recognition Number 14-502). For the EZTest-Gas Biological Indicators, tests included viable spore population assay, resistance characteristics study, carrier and primary packaging materials (growth inhibition) {7}------------------------------------------------ evaluation, holding time assessment, and reduced incubation time validation. The results of all studies met the established acceptance criteria. Under equivalent exposure conditions, the resistance characteristics of the EZTest-Gas Biological Indicators were identical when measured in a Biological Indicator Evaluator Resistometer in the presence or absence of a vacuum. The EOGas 4 Endo-SteriTest represents a rigorous challenge to the EOGas 4 sterilization process. Its resistance characteristics are greater than the same biological indicator placed in the worst-case locations of the endoscope validation loads. The performance of the EOGas 4 Endo-SteriTest in the 6-hour gas exposure at 50 ℃ in an EOGas 4 Ethylene Oxide Gas Sterilizer is summarized in Table 3. | EOGas 4 Endo-Steritest | | | | |-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Test | Description | Acceptance Criteria | Result | | EZTest-Gas Biological Indicator Performance Characteristics | | | | | Viable Spore Population Assays | Determine spore population and demonstrate stability within 50% to 300% of the certified value during the claimed shelf life | ≥106 microorganisms per unit; Stable for the stated 2-year shelf life | Meets the specifications for spore population according to 2007 FDA BI guidance and ANSI/AAMI/ISO 11138-1 | | Resistance Characteristics Study | Determine D-value using the fraction negative method | D-value ≥ 3 min; Survival/Kill Time: 15 min; D-values remain ±20% of the stated value for the claimed 2-year shelf life | Meets the specifications for resistance characteristics according to 2007 FDA BI guidance and ANSI/AAMI/ISO 11138-1 | | Growth Inhibition | Evaluate the effect of the carrier and the primary packaging materials for the intended sterilization process | All exposed carriers and packaging components are not bacteriostatic in a worst- case situation | Compliance with 2007 FDA BI guidance and ANSI/AAMI/ISO 11138-1 | | Holding Time Assessment | A series of sub-lethal exposures and population assays to evaluate the effect of the labeled holding time on the resistance characteristics and spore recovery | The resistance characteristics are not altered significantly over a 7-day hold time prior to incubation. | Compliance with 2007 FDA BI guidance | | Recovery Protocols, Medium and Incubation Time | To validate the recovery protocols, medium, and a reduced incubation time per 2007 FDA BI guidance and ANSI/AAMI/ISO 11138-1 | Growth of an inoculum of 10-100 spores of Bacillus atrophaeus after being subjected to the sterilization process. | Compliance with 2007 FDA BI guidance and ANSI/AAMI/ISO 11138-1; Data generated supports an incubation time of 48 hours for EZTest-Gas biological indicators. | | D-Value Comparison for EZTest-Gas Biological Indicator | | | | | D-value | Determine D-value using a fraction negative method | D-values are within 20% of the original stated values for all lots of biological indicators tested. | There is no significant difference in the D-values measured in a vacuum BIER vs. an A-BIER. | | Performance Testing for the EOGas 4 Endo-SteriTest | | | | | Half Dose Validation | To demonstrate that the EOGas 4 Endo-SteriTest presents a rigorous challenge to the sterilization process | Device is appropriate for monitoring the efficacy of the sterilization process claimed | Partial kill of biological indicators in PCD in half dose cycles, and complete kill in full dose cycles; Biological indicators at the worst-case locations in the endoscope loads are completely inactivated in both half and full dose cycles; EO concentration in the full dose cycles are twice the concentration in the half dose cycles for each endoscope load. | | Pass/Fail Results from the EOGas 4 Sterilizer | To validate EOGas 4 Endo-SteriTest against the duodenoscope and colonoscope loads indicated for processing in the EOGas 4 sterilizer | Correctly indicate pass/fail in cycles | Data demonstrate the EOGas 4 Endo-SteriTest correctly indicates passed and failed 6-hour gas exposures in the EOGas 4 throughout the stated shelf life. | | Endpoint Color Stability of the Chemical Indicator | To evaluate the stability of the endpoint color of the chemical indicator on the biological indicator | Stability to provide reasonable assurance of effectiveness | The endpoint green/brown color was stable for at least 28 days when EZTest-Gas BIs were stored at 20-25°C or at 35-39°C after the EOGas 4 sterilization cycles. | | Shelf Life | To demonstrate the stability of the resistance characteristics and correctly indicate pass/fail in cycles throughout the stated shelf life | Stability of the D-Value and spore population; Correctly indicate pass/fail in cycles | Maintains performance specifications throughout the stated shelf life of 2 years | Table 3. Summary of bench tests performed to demonstrate safety and effectiveness of the EOGas 4 Endo-SteriTest {8}------------------------------------------------ # Conclusion: The conclusions drawn from the nonclinical tests demonstrate that the EOGas 4 Endo-SteriTest is as safe, as effective, and performs as well as or better than the legally marketed EOGas 4 SteriTest (K151585).

EOGas 4 Endo-SteriTest

Device Facts

Indications for Use

Device Story

Clinical Evidence

Technological Characteristics

Indications for Use

Regulatory Classification

Identification

Predicate Devices

Submission Summary (Full Text)

Panel 1

Section Matches

Product Code Matches

Special Control Matches

My Alerts

EOGas 4 Endo-SteriTest

Device Facts

Indications for Use

Device Story

Clinical Evidence

Technological Characteristics

Indications for Use

Regulatory Classification

Identification

Predicate Devices

Submission Summary (Full Text)

Panel 1

Section Matches

Product Code Matches

Special Control Matches

My Alerts

Create Alert

Search Filters

Agent Token

Connected apps

Welcome

Check your email

Welcome!